[go: up one dir, main page]

GT201300006A - Agentes terapèuticos 976 - Google Patents

Agentes terapèuticos 976

Info

Publication number
GT201300006A
GT201300006A GT201300006A GT201300006A GT201300006A GT 201300006 A GT201300006 A GT 201300006A GT 201300006 A GT201300006 A GT 201300006A GT 201300006 A GT201300006 A GT 201300006A GT 201300006 A GT201300006 A GT 201300006A
Authority
GT
Guatemala
Prior art keywords
therapentutic
agents
obesity
compounds
phenylitio
Prior art date
Application number
GT201300006A
Other languages
English (en)
Inventor
B Kman-Winiwarter Susanne Doris Margit
Fredenwall Marlene
Hogner Anders Carl
Johansson Lars Anders
Judkins Robert Andrew
Lanna Li
L Fberg Bjorn Christian Ingvar
Von Unge Per Oskar Sverker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300006A publication Critical patent/GT201300006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A CIERTOS COMPUESTOS SUSTITUIDOS DE (3-(4-(AMINOMETIL)FENOXI O FENILITIO)AZETIDIN-1-IL)(5-FENIL-1,3,4-OXADIAZOL-2-IL)METANONA DE FÓRMULA I, A PROCESOS PARA PREPARAR TALES COMPUESTOS, A SU USO EN EL TRATAMIENTO DE UNA ENFERMEDAD O AFECCIÓN RELACIONADA CON LA HORMONA CONCENTRADORA DE MELANINA, POR EJEMPLO, LA OBESIDAD, AFECCIONES RELACIONADAS CON LA OBESIDAD, ANSIEDAD Y DEPRESIÓN, Y A COMPOSICIONES QUE LOS CONTIENEN.
GT201300006A 2010-07-06 2013-01-04 Agentes terapèuticos 976 GT201300006A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36158510P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
GT201300006A true GT201300006A (es) 2014-11-06

Family

ID=44514822

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300006A GT201300006A (es) 2010-07-06 2013-01-04 Agentes terapèuticos 976

Country Status (26)

Country Link
US (1) US8546375B2 (es)
EP (1) EP2590969B1 (es)
JP (1) JP5827683B2 (es)
KR (1) KR20130041177A (es)
CN (1) CN103209979B (es)
AR (1) AR082113A1 (es)
AU (1) AU2011275547B2 (es)
BR (1) BR112013000296A2 (es)
CA (1) CA2802832A1 (es)
CL (1) CL2013000027A1 (es)
CR (1) CR20130005A (es)
CU (1) CU20130004A7 (es)
DO (1) DOP2013000004A (es)
EA (1) EA201291384A1 (es)
EC (1) ECSP13012369A (es)
ES (1) ES2527466T3 (es)
GT (1) GT201300006A (es)
MX (1) MX2012015102A (es)
NI (1) NI201200196A (es)
PE (1) PE20130781A1 (es)
PH (1) PH12013500027A1 (es)
SA (1) SA111320581B1 (es)
SG (1) SG186275A1 (es)
TW (1) TW201206916A (es)
UY (1) UY33487A (es)
WO (1) WO2012004588A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
CN108840812B (zh) * 2018-06-29 2020-08-18 南京富润凯德生物医药有限公司 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4212867A (en) * 1977-03-03 1980-07-15 Philagro 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them
DE3039087A1 (de) 1980-10-16 1982-05-19 Hoechst Ag, 6000 Frankfurt 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
CA2126976A1 (en) 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
KR970705560A (ko) 1995-08-02 1997-10-09 호아껭 우리아치 토렐로 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
US7541477B2 (en) 2002-07-30 2009-06-02 Banyu Pharmaceutical Co., Ltd. Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
BRPI0513777A (pt) 2004-07-26 2008-05-13 Lilly Co Eli composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo
EP1805169B1 (en) 2004-10-18 2008-12-24 Eli Lilly And Company Histamine h3 receptor inhibitors, their preparation and therapeutic uses
WO2006066173A2 (en) 2004-12-17 2006-06-22 Eli Lilly And Company Novel mch receptor antagonists
EP1831194A4 (en) 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
CA2610671A1 (en) 2005-05-31 2006-12-07 Astrazeneca Ab Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
EP1907398A1 (en) 2005-07-15 2008-04-09 AstraZeneca AB Therapeutic agents
UY30079A1 (es) 2006-01-06 2007-08-31 Astrazeneca Ab Compuestos
CA2659155A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
EP2121703A4 (en) 2006-08-18 2011-12-28 Astrazeneca Ab THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
US8158643B2 (en) 2006-12-05 2012-04-17 Janssen Pharmaceutica N.V. Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases
EA015559B1 (ru) * 2006-12-14 2011-08-30 Эли Лилли Энд Компани ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
EP2148931A2 (en) 2007-04-17 2010-02-03 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
CA2694499A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
BRPI0815674A2 (pt) 2007-08-22 2015-02-18 Hoffmann La Roche Aril-éter de pirrolidina como antagonista de receptor de nk3
BRPI0818581A2 (pt) * 2007-10-17 2015-07-21 Sanofi Aventis Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
US8124636B2 (en) 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
CA2721303C (en) * 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
EP2464632A1 (en) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers

Also Published As

Publication number Publication date
JP5827683B2 (ja) 2015-12-02
AR082113A1 (es) 2012-11-14
AU2011275547B2 (en) 2015-10-29
EP2590969B1 (en) 2014-10-15
MX2012015102A (es) 2013-05-01
US20120010189A1 (en) 2012-01-12
SA111320581B1 (ar) 2014-06-17
UY33487A (es) 2012-02-29
CL2013000027A1 (es) 2013-03-08
TW201206916A (en) 2012-02-16
HK1182712A1 (en) 2013-12-06
DOP2013000004A (es) 2013-04-30
US8546375B2 (en) 2013-10-01
SG186275A1 (en) 2013-01-30
BR112013000296A2 (pt) 2019-09-24
CN103209979A (zh) 2013-07-17
PH12013500027A1 (en) 2017-10-25
PE20130781A1 (es) 2013-07-20
WO2012004588A3 (en) 2012-08-09
WO2012004588A2 (en) 2012-01-12
CU20130004A7 (es) 2013-05-31
EP2590969A2 (en) 2013-05-15
EA201291384A1 (ru) 2013-07-30
CA2802832A1 (en) 2012-01-12
NI201200196A (es) 2013-10-16
ES2527466T3 (es) 2015-01-26
CR20130005A (es) 2013-04-17
AU2011275547A1 (en) 2013-02-07
CN103209979B (zh) 2016-02-10
JP2013535413A (ja) 2013-09-12
KR20130041177A (ko) 2013-04-24
ECSP13012369A (es) 2013-01-31

Similar Documents

Publication Publication Date Title
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
PE20151067A1 (es) Inhibidores de autotaxina
PE20120250A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano, forma farmaceutica de la misma, procedimiento para su preparacion
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
CL2007001887A1 (es) Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
GT201400111A (es) Triazolopiridinas sustituidas
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
CR20120264A (es) Compuestos
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2012003009A1 (es) Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct.
UY33379A (es) Compuestos de morfolina
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
DOP2012000006A (es) Agonista de gpr119
CL2013003527A1 (es) Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc.
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CL2008000438A1 (es) Compuestos derivados de heterociclos sustituidos, agonistas de adrenoreceptores alfa 2c; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar rinitis alergica, glaucoma, insuficiencia cardiaca congestiva, esquizofrenia ent
DOP2013000300A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
CL2010000804A1 (es) Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer.